News Details

Ligand OmniAbĀ® Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis

About Immunovant, Inc.

Price Chart